Below are the most recent publications written about "Antimalarials" by people in Profiles.
-
Gaur AH, Panetta JC, Smith AM, Dallas RH, Freeman BB, Stewart TB, Tang L, John E, Branum KC, Patel ND, Ost S, Heine RN, Richardson JL, Hammill JT, Bebrevska L, Gusovsky F, Maki N, Yanagi T, Flynn PM, McCarthy JS, Chalon S, Guy RK. Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development. EBioMedicine. 2022 Jun; 80:104065.
-
Sharma P, McAlinden KD, Ghavami S, Deshpande DA. Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check? Eur J Pharmacol. 2021 Apr 15; 897:173928.
-
Salacup G, Lo KB, Gul F, Peterson E, De Joy R, Bhargav R, Pelayo J, Albano J, Azmaiparashvili Z, Benzaquen S, Patarroyo-Aponte G, Rangaswami J. Characteristics and clinical outcomes of COVID-19 patients in an underserved-inner city population: A single tertiary center cohort. J Med Virol. 2021 01; 93(1):416-423.
-
Thome R, Casella G, Lotfi N, Ishikawa LWL, Wang Q, Ciric B, Zhang GX, Rostami A. Primaquine elicits Foxp3+ regulatory T cells with a superior ability to limit CNS autoimmune inflammation. J Autoimmun. 2020 11; 114:102505.
-
Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, Muyembe TamFum JJ, Seydi M, Eholie SP, Mills EJ, Kallay O, Zumla A, Nachega JB. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. Am J Trop Med Hyg. 2020 06; 102(6):1184-1188.
-
Thome R, Boehm A, Ishikawa LLW, Casella G, Munhoz J, Ciric B, Zhang GX, Rostami A. Chloroquine reduces Th17 cell differentiation by stimulating T-bet expression in T cells. Cell Mol Immunol. 2021 03; 18(3):779-780.
-
Gaur AH, McCarthy JS, Panetta JC, Dallas RH, Woodford J, Tang L, Smith AM, Stewart TB, Branum KC, Freeman BB, Patel ND, John E, Chalon S, Ost S, Heine RN, Richardson JL, Christensen R, Flynn PM, Van Gessel Y, Mitasev B, M?hrle JJ, Gusovsky F, Bebrevska L, Guy RK. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Lancet Infect Dis. 2020 08; 20(8):964-975.
-
Ackert J, Mohamed K, Slakter JS, El-Harazi S, Berni A, Gevorkyan H, Hardaker E, Hussaini A, Jones SW, Koh GCKW, Patel J, Rasmussen S, Kelly DS, Bara?ano DE, Thompson JT, Warren KA, Sergott RC, Tonkyn J, Wolstenholme A, Coleman H, Yuan A, Duparc S, Green JA. Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers. Drug Saf. 2019 09; 42(9):1103-1114.
-
Karadag AS, Parish LC. Sarcoidosis: A great imitator. Clin Dermatol. 2019 May - Jun; 37(3):240-254.
-
Kamuliwo M, Kirk KE, Chanda E, Elbadry MA, Lubinda J, Weppelmann TA, Mukonka VM, Zhang W, Mushinge G, Mwanza-Ingwe M, Haque U. Spatial patterns and determinants of malaria infection during pregnancy in Zambia. Trans R Soc Trop Med Hyg. 2015 Aug; 109(8):514-21.